Bristol-Myers Squibb Co. has signed a definitive agreement to acquire Padlock Therapeutics, Inc., a private, Cambridge, MA-based biotechnology company focused on medicines to treat destructive autoimmune diseases. BMS gains full rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program focused on transformational treatment approaches for rheumatoid arthritis (RA), as well as systemic lupus erythematosus (SLE) and other autoimmune diseases.   The transaction incl...